Rapamycin in Relapsed Acute Lymphoblastic Leukemia.

Trial Profile

Rapamycin in Relapsed Acute Lymphoblastic Leukemia.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Nov 2016

At a glance

  • Drugs Sirolimus (Primary) ; Corticosteroids; Corticosteroids
  • Indications Acute lymphoblastic leukaemia
  • Focus Pharmacodynamics
  • Most Recent Events

    • 01 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 12 Feb 2016 Planned End Date changed from 1 Oct 2015 to 1 Apr 2016, according to ClinicalTrials.gov record.
    • 24 Apr 2013 Planned end date changed from 1 Oct 2012 to 1 Oct 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top